Literature DB >> 8978965

Y box-binding trans-regulatory nuclear proteins and susceptibility to rheumatoid arthritis.

D P Singal1, M Ye, H Fleisig, W W Buchanan, X Qiu.   

Abstract

OBJECTIVE: Inappropriately high levels of expression of HLA-DR molecules or their expression on inappropriate cells, e.g. synovial tissue and T cells, may result in an aberrant tissue-destructive immune response and thus cause susceptibility to rheumatoid arthritis (RA).
METHODS: Patients and controls were typed for HLA-DR antigens by oligonucleotide typing of PCR-amplified DNA. Trans-regulatory nuclear proteins that bind to the Y box in DRB promotors were examined by the gel-mobility shift assay.
RESULTS: We found that the trans-regulatory nuclear protein (NF-Y), which binds to the Y box in DRB promoters and which plays a dominant role on the level of the expression and inducibility of DR genes, was absent in 50% of RA patients but not in healthy individuals (0%). Furthermore, we observed that all patients (100%) either lacked the NF-Y protein and/or carried the disease susceptibility DRB1 gene, which gives the highest relative risk value (RR = 46.6; p < 1.6 x 10(-6)) reported so far for susceptibility to RA.
CONCLUSION: The absence of the trans-regulatory nuclear protein that binds to the Y box with an inverted CCAAT motif in DRB promotors and the presence of the DRB1 gene with the amino acid motif QKRAA and QRRAA cause susceptibility to RA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8978965

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  2 in total

Review 1.  Impaired regulation of HLA-DR expression in human immunodeficiency virus-infected monocytes.

Authors:  Ling Shao; Kirk Sperber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

2.  Identification of transcription regulatory relationships in rheumatoid arthritis and osteoarthritis.

Authors:  Guofeng Li; Ning Han; Zengchun Li; Qingyou Lu
Journal:  Clin Rheumatol       Date:  2013-01-08       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.